



# Rituximab: prescribe by brand

## What's changing?

Between **1 March 2020 to 1 December 2020** we will be transitioning patients from Mabthera to Riximyo.

- **Riximyo** is the newly funded brand and will be funded for people using rituximab for all conditions except rheumatoid arthritis.
- **Mabthera** will remain funded for people with rheumatoid arthritis.

If you have any questions contact:



PHARMAC  
TE PĀTAKA WHAIORANGA